Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 1658397, 7 pages
https://doi.org/10.1155/2017/1658397
Clinical Study

Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity

Department of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan

Correspondence should be addressed to Ying-Chou Chen; ten.tenih.31sm@317028r

Received 21 January 2017; Revised 16 June 2017; Accepted 6 July 2017; Published 6 September 2017

Academic Editor: Mónica Vázquez-Del Mercado

Copyright © 2017 Ying-Chou Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Grinnell and M. K. Feld, “Fibronectin adsorption on hydrophilic and hydrophobic surfaces detected by antibody binding and analyzed during cell adhesion in serum-containing medium,” The Journal of Biological Chemistry, vol. 257, no. 9, pp. 4888–4893, 1982. View at Google Scholar
  2. L. B. van de Putte, C. Atkins, M. Malaise et al., “Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed,” Annals of the Rheumatic Diseases, vol. 63, no. 5, pp. 508–516, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. L. B. van de Putte, R. Rau, F. C. Breedveld et al., “Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study,” Annals of the Rheumatic Diseases, vol. 62, no. 12, pp. 1168–1177, 2003. View at Google Scholar
  4. P. Emery, “Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control,” Drugs of Today (Barcelona, Spain: 1998), vol. 39, Supplement B, pp. 17–23, 2003. View at Google Scholar
  5. E. C. Keystone, A. F. Kavanaugh, J. T. Sharp et al., “Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial,” Arthritis and Rheumatism, vol. 50, no. 5, pp. 1400–1411, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Szkudlarek, E. Narvestad, M. Klarlund, M. Court-Payen, H. S. Thomsen, and M. Ostergaard, “Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination,” Arthritis and Rheumatism, vol. 50, no. 7, pp. 2103–2112, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Schirmer, C. Duftner, W. A. Schmidt, and C. Dejaco, “Ultrasonography in inflammatory rheumatic disease: an overview,” Nature Reviews. Rheumatology, vol. 7, no. 8, pp. 479–488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Lainer-Carr and E. Brahn, “Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis,” Nature Clinical Practice Rheumatology, vol. 3, no. 8, pp. 434–442, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Naredo, P. Collado, A. Cruz et al., “Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression,” Arthritis and Rheumatism, vol. 57, no. 1, pp. 116–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Kitchen and D. Kane, “Greyscale and power Doppler ultrasonographic evaluation of normal synovial joints: correlation with pro- and anti-inflammatory cytokines and angiogenic factors,” Rheumatology (Oxford), vol. 54, no. 3, pp. 458–462, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Ostergaard, M. Hansen, M. Stoltenberg et al., “Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 42, no. 5, pp. 918–929, 1999. View at Publisher · View at Google Scholar
  12. S. Shiozawa, K. Shiozawa, and T. Fujita, “Morphologic observations in the early phase of the cartilage-pannus junction. Light and electron microscopic studies of active cellular pannus,” Arthritis and Rheumatism, vol. 26, no. 4, pp. 472–478, 1983. View at Google Scholar
  13. S. Shiozawa and M. Ziff, “Immunoelectron microscopic demonstration of fibronectin in rheumatoid pannus and at the cartilage-pannus junction,” Annals of the Rheumatic Diseases, vol. 42, no. 3, pp. 254–263, 1983. View at Google Scholar
  14. S. Carsons, M. W. Mosesson, and H. S. Diamond, “Detection and quantitation of fibronectin in synovial fluid from patients with rheumatic disease,” Arthritis and Rheumatism, vol. 24, no. 10, pp. 1261–1267, 1981. View at Google Scholar
  15. M. Lu-Steffes, A. J. Iammartino, F. R. Schmid et al., “Fibronectin in rheumatoid and non-rheumatoid arthritic synovial fluids and in synovial fluid cryoproteins,” Annals of Clinical and Laboratory Science, vol. 12, no. 3, pp. 178–185, 1982. View at Google Scholar
  16. G. Weissmann, E. Pearlstein, H. D. Perez, S. Falkow, I. M. Goldstein, and S. T. Hoffstein, “Neutrophils synthesize and deposit fibronectin on surfaces to which they attach,” Transactions of the Association of American Physicians, vol. 93, pp. 72–84, 1980. View at Google Scholar
  17. F. Grinnell and M. K. Feld, “Initial adhesion of human fibroblasts in serum-free medium: possible role of secreted fibronectin,” Cell, vol. 17, no. 1, pp. 117–129, 1979. View at Google Scholar
  18. H. Hormann and V. Jelinic, “Fibronectin, VII. Binding of cold-insoluble globulin and of denatured collagen by macrophages,” Hoppe-Seyler's Zeitschrift fur physiologische Chemie, vol. 361, no. 3, pp. 379–387, 1980. View at Google Scholar
  19. M. Kurkinen, A. Vaheri, P. J. Roberts, and S. Stenman, “Sequential appearance of fibronectin and collagen in experimental granulation tissue,” Laboratory Investigation; a Journal of Technical Methods and Pathology, vol. 43, no. 1, pp. 47–51, 1980. View at Google Scholar
  20. J. C. Mavropoulos, M. Cuchacovich, C. Llanos et al., “Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 32, no. 11, pp. 2116–2124, 2005. View at Google Scholar
  21. Y. C. Chen, F. M. Su, S. W. Hsu et al., “Predictor of hand radiological progression in patients with rheumatoid arthritis receiving TNF antagonist therapy by change in grayscale synovitis-a preliminary study,” Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, vol. 23, no. 2, pp. 73–76, 2017. View at Publisher · View at Google Scholar
  22. U. M. Dohn, B. Ejbjerg, A. Boonen et al., “No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study,” Annals of the Rheumatic Diseases, vol. 70, no. 2, pp. 252–258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. S. Smolen, P. Emery, R. Fleischmann et al., “Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial,” Lancet, vol. 383, no. 9914, pp. 321–332, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. E. C. Keystone, F. C. Breedveld, D. van der Heijde et al., “Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension,” The Journal of Rheumatology, vol. 41, no. 1, pp. 5–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Ellegaard, R. Christensen, S. Torp-Pedersen et al., “Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study,” Rheumatology (Oxford), vol. 50, no. 3, pp. 506–512, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Ellegaard, S. Torp-Pedersen, R. Christensen et al., “Feasibility of a standardized ultrasound examination in patients with rheumatoid arthritis: a quality improvement among rheumatologists cohort,” BMC Musculoskeletal Disorders, vol. 13, p. 35, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Terslev, K. Ellegaard, R. Christensen et al., “Head-to-head comparison of quantitative and semi-quantitative ultrasound scoring systems for rheumatoid arthritis: reliability, agreement and construct validity,” Rheumatology (Oxford), vol. 51, no. 11, pp. 2034–2038, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Andersen, K. Ellegaard, J. B. Hebsgaard et al., “Ultrasound colour Doppler is associated with synovial pathology in biopsies from hand joints in rheumatoid arthritis patients: a cross-sectional study,” Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 678–683, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Y. Kawashiri, T. Suzuki, Y. Nakashima et al., “Synovial inflammation assessed by ultrasonography correlates with MRI-proven osteitis in patients with rheumatoid arthritis,” Rheumatology (Oxford), vol. 53, no. 8, pp. 1452–1456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Fukae, K. Tanimura, T. Atsumi, and T. Koike, “Sonographic synovial vascularity of synovitis in rheumatoid arthritis,” Rheumatology (Oxford), vol. 53, no. 4, pp. 586–591, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Fukae, M. Isobe, A. Kitano et al., “Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint,” Rheumatology (Oxford), vol. 52, no. 3, pp. 523–528, 2013. View at Publisher · View at Google Scholar · View at Scopus